Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › RNA virus infections

RNA virus infections

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for RNA virus infections

10 trials tracked for RNA virus infections: 5 in phase 3 or 4 and 4 with published results. The most-cited published study has 192 citations.

10Trials tracked
5Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 3 5 Phase 2 4 Other / NA 1
  1. Phase 3 Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults Completed · 192 cited
  2. Phase 3 Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly Completed · 192 cited
  3. Phase 3 Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults Completed · 72 cited
  4. Phase 3 A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety Completed · 20 cited
  5. Phase 3 Convalescent Plasma Collection and Treatment in Pediatrics and Adults Completed
  6. Phase 2 A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed Completed
Show 4 more trials
  1. Phase 2 Study of Interferon-Gamma in the Complex Treatment of Patients Infected With HIV and Tuberculosis Completed
  2. Phase 2 VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents Completed
  3. Phase 2 A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults Completed
  4. N/A Self-Test Strategies and Linkage Incentives to Improve ART and PrEP Uptake in Men Completed

Showing the 10 most-cited and recently-updated of 10 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

RNA virus infections: what the trials found

New evidence indicates that Convalescent Plasma is an established intervention for RNA virus infections 1. Additionally, the SYN023 vaccine demonstrated high efficacy in inducing Rabies Virus Neutralizing Activity (RVNA) ≥0.5 IU/mL across multiple study arms, with results ranging from 9.1% to 100% 6.

Multiple Quadrivalent VLP vaccines were evaluated for influenza and other strains. One trial showed seroprotection rates between 39.2% and 74.8% across various strains 3, while another demonstrated seroprotection rates ranging from 48.5% to 87.9% 4. A specific Quadrivalent VLP Influenza Vaccine showed high seroprotection (SP) rates, with values between 76.5% and 98.7%, and significant Geometric Mean Fold Rise (GMFR) in HI antibody responses ranging from 7.69 to 8.99 5.

Recent results — preliminary, needs further review

  • aH5N6c administered on Day 1 showed a Geometric Mean Fold Increase (GMFI) of HI Antibodies against the H5N6 strain ranging from 1.45 to 12.13; seroconversion rates for this intervention were reported between 9.6% and 37.3% 2.

For the clinician treating this condition

  • Convalescent Plasma is an established treatment option in the context of RNA virus infections 1.
  • SYN023 shows high rates of Rabies Virus Neutralizing Activity (RVNA) 6.
  • Quadrivalent VLP vaccines demonstrate consistent seroprotection and significant HI antibody responses for influenza and other strains [3, 4, 5].

AI synthesis of 6 cited trials, updated Jul 18, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this condition. Check back soon.